Cadence M is the second clinical trial in the Cadence series*
The trial aims to determine if receiving an extract from the rind of the tropical fruit mangosteen, in addition to regular treatments, assists with the treatment of schizophrenia.
Mangosteen is a tropical evergreen fruit tree originating in Indonesia. The thick purple rind (pericarp) of the fruit contains a number of compounds called xanthones that show promise in the treatment of schizophrenia.
Many of the most valuable drugs in medicine are plant-derived (e.g. morphine, quinine). Pilot studies suggest that certain xanthones derived from mangosteen pericarp significantly reduce the symptoms of schizophrenia.
We now seek to replicate the results of the pilot study in a larger, multi-site trial.
This research has been initiated by the Coordinating Principal Investigator Professor Michael Berk (Deakin University) and Principal Investigator Professor John McGrath (The University of Queensland).
*The Cadence M trial is also known as Mango SZ at our companion site in Geelong.
Cadence M is supported by the Stanley Medical Research Institute.
Illustration from Fleurs, Fruits et Feuillages Choisis de l'Ile de Java1863-1864 by Berthe Hoola van Nooten (Pieter De Pannemaeker lithographer)